Larvol Delta - Celyad-Oncology-Reports-First-Half-Year-2024-Financial-Results-and-Recent-Business-Highlights

PSMA/NKG2DL multispecific CAR T - Celyad Oncology

CYAD-221 - Celyad Oncology

https://www.businesswire.com/news/home/20240912537151/en/Celyad-Oncology-Reports-First-Half-Year-2024-Financial-Results-and-Recent-Business-Highlights

Sep 15, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next